Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer

Alaa G Almagthali; Eman H Alkhaldi; Afnan S Alzahrani; Ameera K Alghamdi; Waleed Y Alghamdi; Ahmed M Kabel

doi:10.1016/j.dsx.2018.08.012

Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer

Diabetes Metab Syndr. 2019 Jan-Feb;13(1):36-39. doi: 10.1016/j.dsx.2018.08.012. Epub 2018 Aug 10.

Authors

Alaa G Almagthali¹, Eman H Alkhaldi¹, Afnan S Alzahrani¹, Ameera K Alghamdi¹, Waleed Y Alghamdi¹, Ahmed M Kabel²

Affiliations

¹ Pharm D, College of Pharmacy, Taif University, Taif, Saudi Arabia.
² Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia; Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: [email protected].

PMID: 30641726
DOI: 10.1016/j.dsx.2018.08.012

Abstract

Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.

Keywords: Cancer; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitors; Patients.

Publication types

Review

MeSH terms

Animals
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Humans
Hypoglycemic Agents / therapeutic use*
Neoplasms / prevention & control*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents